The demand for Lipid-Lowering Agents in Tunisia has been growing steadily over the years.
Customer preferences: The Tunisian market for Lipid-Lowering Agents is largely driven by an aging population and a high prevalence of cardiovascular diseases. Patients are becoming increasingly aware of the importance of maintaining healthy cholesterol levels and are seeking medical intervention to achieve this goal. Additionally, there is a growing preference for combination therapies that offer more comprehensive treatment options.
Trends in the market: The market for Lipid-Lowering Agents in Tunisia is witnessing a shift towards generic drugs due to their affordability and accessibility. This trend is expected to continue in the coming years as the government continues to promote the use of generic drugs to reduce healthcare costs. Furthermore, there is a growing demand for innovative therapies that offer better efficacy and safety profiles. This has led to an increase in research and development activities in the market, with several new drugs in the pipeline.
Local special circumstances: The Tunisian government has implemented several policies to promote the use of Lipid-Lowering Agents, including the inclusion of these drugs in the national essential medicines list and the provision of subsidies for low-income patients. Additionally, the government has established several programs to increase awareness about cardiovascular diseases and encourage early detection and treatment.
Underlying macroeconomic factors: The Tunisian economy has been growing steadily over the years, with a focus on diversifying the economy and promoting foreign investment. This has led to an increase in healthcare spending and the development of a more robust healthcare infrastructure. Furthermore, the government has implemented several policies to improve access to healthcare services and reduce healthcare costs, which has had a positive impact on the Lipid-Lowering Agents market. However, the market is still facing several challenges, including a lack of adequate reimbursement policies and the presence of counterfeit drugs in the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
